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Abstract
Regulatory T-cells (TReg cells) are increased in patients with multiple myeloma (MM). We investigated whether MM cells
could generate and/or expand TReg cells as a method of immuno-surveillance avoidance. In an in vitro model,
CD4+CD25-FoxP3- T-cells co-cultured with malignant plasma cells (primary MM cells and cell lines) induced a significant
generation of CD4+CD25+FoxP3+ inducible TReg cells (tTReg cells; p,0.0001), in a contact-dependent manner. tTReg cells were
polyclonal, demonstrated a suppressive phenotype and phenotypically, demonstrated increased FoxP3 (p = 0.0001),
increased GITR (p,0.0001), increased PD1 (p = 0.003) and decreased CD62L (p = 0.007) expression compared with naturally
occurring TReg cells. FACS-sorted tTReg cells differentiated into FoxP
+IL-17+ and FoxP3-IL-17+ CD4+ cells upon TCR-mediated
stimulation. Blocking experiments with anti-ICOS-L MoAb resulted in a significant inhibition of tTReg cell generation whereas
both IL-10 & TGFb blockade did not. MM tumour cells can directly generate functional TReg cells in a contact-dependent
manner, mediated by ICOS/ICOS-L. These features suggest that tumour generation of TReg cells may contribute to evasion of
immune surveillance by the host.
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Introduction
The paradoxical observation of tumor growth despite an
attempt by the tumour-bearing host immune system to control
and eliminate the malignant cells suggests that the anti-tumour
immune response is being attenuated limiting competent immune
surveillance (reviewed in [1]). This has been extensively studied by
tumour immune-biologists, with results pointing towards soluble
factors and altered antigenicity as mechanistic explanations. More
recently, with the discovery of a number of different immune-
regulatory cell types, focus has shifted towards cellular mediated
tumour-induced immune suppression and evasion. Several differ-
ent subsets of regulatory T-cells have now been identified
including naturally occurring TReg cells (nTReg cells:
CD4+CD25+FoxP3+), and inducible Tr1 and TH3 CD4
+TReg cells
[2] as well as CD8+ TReg cells [3] and Double Negative TReg cells.
Originally it was thought that TReg cells were centrally generated
in the thymus, though more recently evidence suggests that
peripheral generation is also possible, thereby providing a
biological back-drop to investigating their role in the cancer-
bearing host [4,5]. In fact, several studies have shown that
increased levels of TReg cells can be found in a variety of solid
tumours [6,7] and haematological malignancies [8,9,10].
Multiple Myeloma (MM), an incurable malignant plasma cell
dyscrasia, is associated with both cellular and humoral immune
deficiencies [11]. Many potential mediators of the immunologically
hostile microenvironment have been proposed including tumour-
derived TGFb [12], Prostaglandin E2 (PGE2) and Interleukin-10
(IL-10) [13]. In addition to soluble mediators, we and others have
demonstrated that TReg cell subsets are functional and increased in
the peripheral blood of patients with MM, associated with their
disease burden [14]. In particular, we demonstrated a higher level
in the ‘‘pre-myelomatous’’ condition, MGUS but to a lesser extent
than when full disease is present though higher levels of IL-10 were
seen in the PB of MGUS compared with patients with MM. In light
of this recent evidence, it would now seem that the most promising
and synergistic approaches for cancer immunotherapy will be
strategies that augment specific anti-tumor immunity whilst
simultaneously reducing the effect of tumour-induced immune-
regulation. However, in order to perform this later component, a
greater understanding of the in vivo mechanism of tumour-induced
immune suppression is needed.
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In this study, using an in vitro model system, we demonstrate that
the tumour cells of MM are not only capable of expanding nTReg
cells but generating TReg cells de novo, mediated through cell
contact. Through our experimentation, we demonstrate that
surface ICOS-L on the tumour cells mediates this phenomenon
and that the tumour-induced TReg cells whilst sharing some are
phenotypic features also display phenotypic differences but are
functionally similar to nTReg cells. The data presented here
provides further evidence of direct tumour manipulation of the
immune system to augment immune evasion and propagation of
the malignant cell clone.
Materials and Methods
Cell Lines, Culture Medium and Reagents
The human MM cell lines (HMCL) U266B, KMS11, JIM3,
JJN3 and RPMI8226 (in house) were expanded in mycoplasma-
free cultures, maintained in complete tissue culture medium (CM:
RPMI 1640 medium, 10% FCS, 2 mM L-Glutamine, 100 iu/ml
penicillin, 100 mg/ml streptomycin) in ventilated tissue culture
flasks at 37uCelsius in a 5% CO2 humidified incubator
[15,16,17,18,19]. The HMCL used in co-culture were HLA class
II positive (HLA-DR+), in particular expressing HLA-DR. HMCL
were treated with 50 mg/ml Mitomycin C in CM for 30 minutes at
37uC, followed by 2 washes in CM, to limit tumour cell
proliferation in the co-culture. Directly conjugated mAbs against
CD4-APC, CD8-APC, CD3-PerCP, CD25-PE (all from BD
Biosciences, Oxford, UK), FoxP3-FITC (eBioscience, San Diego,
USA), ICOS-PE (BD clone DX29, BD Biosciences, Oxford, UK)
and IL-17A-APC-A (eBioscience clone eBio64DEC17,
eBioscience, San Diego, USA) were used according to the
manufacturer’s protocol with corresponding isotype-matched
controls.
Primary samples were obtained from patients with myeloma
(n = 9) through iliac crest aspirations. The study was approved by
the local ethics committee and written informed consent was
obtained (NRES Committee Yorkshire & The Humber – Leeds
East: Ref 04/Q1206/147). All samples were collected in sterile
EDTA containers and mononuclear cells (MNC) were isolated by
density gradient centrifugation on Lymphoprep (Axis-Shield, UK)
and stored in foetal calf serum with 10% DMSO in the vapour
phase of liquid nitrogen at -270uC until the day of analysis.
In vitro Modeling of Tumour Cell and T-cell Interactions
Mononuclear cell (MNC) preparations were made from
leukocyte concentrates provided by the National Blood Service.
MNC were isolated by density gradient centrifugation on
Lymphoprep (Axis-Shield, UK) and washed three times in PBS
before use in the culture system. Peripheral blood lymphocyte
(PBL) preparations were made by monocyte-depletion of the
MNC fraction through plastic adherence by 2-hour incubation of
MNC in CM at 37uC. Mitomycin C-treated HMCL were added
to MNC/PBL with a responder:HMCL ratio of 2:1 at
16106 PBMC/ml with MNC-only controls treated the same
way. Supernatants were collected on day 7 of culture and frozen
immediately at 280uC for later cytokine assessment. Cells were
harvested on the same days for analysis by Flow cytometry.
Cell Sorting and FACS Analysis
Four-colour flow cytometry was performed on a LSRII (BD
Biosciences) and analysed with FACS DIVA software. Directly
conjugated mAbs against CD4-APC, CD8-APC, CD3-PerCP,
CD25-PE (all from BD Biosciences, Oxford, UK) and FoxP3-FITC
(eBioscience, San Diego, USA) were used according to the
manufacturer’s protocol with corresponding isotype-matched
controls. 16106 cells were stained. The fixation and dead cell
discrimination kit (Miltenyi Biotec, Bergisch-Gladbach, Germany)
was used to exclude dead cells within the intracellular staining
protocol. Using a sequential gating strategy, TReg cells were
identified as CD4+CD25+FoxP3+ T-cells and expressed as a
percentage of the CD4+ T-cell population. In order to perform
functional analysis on the in vitro generated TReg cells, cells were
pre-selected through magnetic cell separation by using the CD4
untouched method (Miltenyi Biotec, Bergisch-Gladbach, Ger-
many) according to the manufacturer’s protocol and then FACS
sorted using the surface antibodies CD4-APC, CD25-PE and
CD127-Pacific Blue. Samples were sorted into a
CD4+CD25+CD127- TReg cells and CD4
+CD25-CD127+ effector
T-cells the MoFlo high performance multi-parameter cell sorter.
Proliferation and Suppression Assays
MNC were sorted into CD4+CD25- effector cells and
CD4+CD25+ TReg cells as described above. The CD4
+CD25-
responder cells were plated in 96 well round bottom plates (Nunc
plates, Thermo Fisher Scientific, Roskilde, Denmark) in tripli-
cates at a concentration of 16105 cells per well in CM. Purified
CD4+CD25+ TReg cells were added at different concentrations
(4:1 and 8:1 responder to suppressor ratio). The suppressive
capability of the TReg cell fraction was determined by
3H-
Thymidine incorporation for 18 hours at 1 mCi per well after
72 hours stimulation with CD3/CD28- Antibiotin MACSIbeads
(Miltenyi Biotec, Bergisch-Gladbach, Germany) at a 1 bead:
2 cell concentration. 3H-thymidine incorporation in the stimu-
lated responder only wells was set as 100% and a stimulation
index (SI) calculated. Where indicated, cell populations were
stained with 2 mM CFSE before co-culture and analysed by
FACS.
Th17 T-Cell Analysis
To assess if tumour-generated regulatory T-cells have the same
capability to produce IL17-producing T-cells (Th17 cells) as nTReg
cells, both populations were obtained on day 7 of co-culture with
HMCL and day 0, respectively. Sorted cells populations were
stimulated with anti-CD3 and anti-CD28 coated beads at a cell to
bead ratio of 2:1 and cultured for 5 days in CM at
16106 cells per ml. Six hours prior to intracellular staining,
Brefeldin A (BFA) (10 mg/ml), Ionomycin (1 mM) and phorbol
myristate acetate (PMA) (20 ng/ml) were added. Cells were then
washed and stained as per intracellular staining protocols using the
dead cell discriminator with CD4 Pacific Blue, FoxP3 FITC and
IL-17A AlexaFluor 647 (eBioscience, clone eBio64DEC17), using
their corresponding isotypes as controls, analysed using the LSRII
as described above.
Cytokine Assessment
Capture and detection antibodies were used (BD Biosciences,
Oxford, UK) according to the manufacturers protocol. In short,
high protein binding 96 well ELISA plates (MaxiSorp, Scientific
Laboratory Supplies Ltd., Hessle, UK) were coated at 4uC
overnight with IL-10 and TGFb capture antibodies at 1:500
dilution in 1x 1 M NaHCO3 pH 8.2 at 100 ml per well. For TGFb
ELISA, serum samples were diluted 1:5 with PBS and activated
with 1N HCL at room temperature for 15 minutes and neutralized
with 1N NaOH. After blocking with PBS containing 10% FCS for
2 hrs at room temperature, samples and standards were loaded at
100 ml per well and incubated at 4uC overnight. 100 ml per well
detection antibody was then added at 1:1000 dilution for IL-10
and 1:500 dilution for TGFb and incubated for 2 hrs at room
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temperature followed by Extravidin-Avidin conjugate (100 ml per
well at 1:500 dilution in PBS/Tween for 1 hr) and substrate
solution (Sigma, Dorset, UK) for approximately 30 minutes for
development in the dark. Samples were analysed in triplicate and
measured spectrophotometrically at 405 nm. For LUMINEX
Extracellular assay, spectrally encoded antibody-conjugated
5.6 mm polystyrene beads were used according to the manufac-
turer’s protocol. Plates were pre-wet and 25 ml antibody coated
beads and 200 ml wash solution were added and washed once.
Then, 50 ml incubation buffer was added to 100 ml standard or
50 ml sample/50 ml assay diluents. After a 2 hour incubation and
washing, the plate was then incubated with 100 ml PBS with the
cytokine specific biotinylated detector antibodies. The fluorescent
streptavidin-RPE was added and after incubation was analysed
with the Luminex IS software.
T-cell Receptor Clonality by PCR
T-cell receptor (TCR) clonality was determined by PCR analyses
of TCRG rearrangements as previously described [20]. In brief,
DNA was isolated from FACS sorted cells and subjected to PCR
performed using the BIOMED-2 multiplex strategy (InVivoScribe
Technologies, San Diego, CA). PCR products were labeled in the
6FAM, HEX and NED fluorochromes and Vc usage was identified
using ABI Fluorescence detection. Positive controls for clonal T-cell
populations were derived from the peripheral blood of patients with
T-cell lymphoproliferative disease.
Statistical Analysis
Results were analysed using SPSS version 14.0 for Windows
software. Multiple independent variables were analysed with the
Figure 1. Regulatory T-cell induction by Myeloma tumour cells. A. The expansion of FoxP3+CD25+CD4+ natural TReg cells, expressed as a
percentage of CD4+T-cells. TReg cells were enumerated in the PB of healthy donors, after 7 days in CM and 7 days co-cultured with mitomycin C-
treated U266B cells (n = 4). Results represent all experiments, expressed as mean 6 SEM and analyzed using a 1-way ANOVA and student t-test. B.
Expansion of nTReg cells when co-culture with HMCL results from cell division, illustrated by a representative flow cytometry plot of CFSE dilution. C.
The generation of FoxP3+CD25+CD4+ T-cells, expressed as a percentage of CD4+T-cells, in a co-culture assay with mitomycin C-treated U266B cells
(n = 6) with varying starting populations: PB MNC, PBL CD25 depleted and CD4+CD25- T-cells. Results demonstrate that increased generation of
tumour-induced regulatory T-cells (tTReg cells) is seen with increasing purity of the seeded population. Results represent all experiments, expressed as
mean 6 SEM and analyzed using a 1-way ANOVA and student t-test. D. Representative flow cytometry plots demonstrating the generation of
FoxP3+CD25+CD4+ T-cells from CD4+CD25- T-cells through cell division of de novo generated FoxP3+ T-cells in a 7 day co-culture assay with
mitomycin C-treated U266B cells. E. The generation of FoxP3+CD25+CD4+ T-cells, expressed as a percentage of CD4+T-cells, in a co-culture assay of
CD4+CD252 T-cells (n = 10) with mitomycin C-treated MM cell lines (U266B, JJN3, JIM3 & KMS11), an erythro-leukaemia cell line (K562) and non-
heamatopoietic cell lines (Mel888 & HeLa). Results represent all experiments, expressed as mean 6 SEM and analyzed using a 1-way ANOVA and
student t-test (**p,0.001, *p,0.01). F. The generation of FoxP3+CD25+CD4+ T-cells, expressed as a percentage of CD4+T-cells, in a co-culture assay
with fresh BM-derived myeloma plasma cells from patient samples (n = 7). Results demonstrate that increased generation of tumour-induced
regulatory T-cells (tTReg cells) is seen with primary myeloma cells. Results represent all experiments, expressed as mean 6 SEM and analyzed using a
1-way ANOVA and student t-test.
doi:10.1371/journal.pone.0035981.g001
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Kruskal-Wallis test for non-parametric samples and with the
Mann-Whitney-U test for 2 independent samples. A p-value of
,0.05 was considered statistically significant. Comparison of
patient samples was expressed as median values and co-culture
experiments as mean values.
Results
Malignant Plasma Cells Induce Regulatory T-cell
Generation
We have previously shown an increase in functional TReg cells
in the peripheral blood of patients with MM, relating to the stage
of their disease [14]. To examine the relationship between
myeloma tumour cells and TReg cells, we first determined the
effect of co-culturing naturally-occurring TReg cells (nTReg cells)
with mitomycin-C treated HMCL (U266B HLA-class IIPos). When
nTReg cells were sorted from the PB of healthy volunteers and
cultured in CM alone, a significant reduction in the proportion of
nTReg cells was observed (Day 0:28.0%62.6 vs Day 7:7.3%65.3;
n = 4. p = 0.013). However, if co-cultured with HMCL, nTReg cell
expansion was evident (Day 0:28.0%62.6 vs Day 7:43.5%65;
n = 4, p = 0.029; 1-way ANOVA p = 0.001; Figure 1A and 1C).
We hypothesized that the MM tumour cells could directly induce
TReg cells, in the absence of antigen presenting cells. Firstly we
examined the starting cell population in this model, culturing
MNC and purified CD4+CD25- effector T-cells (antigen-present-
ing cell free population) from healthy donor PB with mitomycin C-
treated HMCLs. MNC from healthy controls contained a mean of
6.2%60.4 CD4+ nTReg cells. nTReg cell depletion was very
effective and achieved a CD25+CD4+ T cell contamination of
0.08%60.05%, representing a.97.5% depletion efficiency (n = 7;
p = 0.0001, Kruskal-Wallis test). Co-culture of unselected MNCs
demonstrated a non-significant increase in TReg cells compared
with controls (Day 0:4.8%61.1 vs Day 7:7.6%61.5; p = 0.06)
which was enhanced when CD4+CD25- T-cells only were seeded
with cell lines (Day 0:0.7%60.3 vs Day 7:31.6%63.6; n = 10,
p,0.001; Figure 1C & D).
Next to determine if this was a MM-specific effect, we co-
cultured CD4+CD25- T-cells with a selection of HMCL (U266,
JJN3, JIM3 & KMS11), a myeloid-derived cell line (K562) and
non-heamatopoietic cell lines (Mel888 & HeLa). A clear induction
of TReg cells was seen with each of the HMCL and K562, but not
the non-haematopoietic cell lines MEL888 or HeLa cell lines
(n = 6, 1-way ANOVA p = 0.0015; Figure 1E). When sorted
primary bone marrow plasma cells taken from patients with
myeloma (n = 7) were co-cultured with CD4+CD25- T-cells from
healthy donors, a significant generation of TReg cells was seen
(1.2%60.31 vs 12.0264.4, n = 7; p = 0.004), similar to the
HMCL, U266B (1.2%60.31 vs 21.9%65.6, n = 7; p,0.0001;
Figure 1F).
Tumour-generated Regulatory T-cells are Phenotypically
Different to Natural TReg Cells
Differences in phenotype between naturally occurring and
inducible TReg cells have been reported [21,22]. We therefore
sought to characterize the phenotype of tTReg cells generated in
our in vitro assay compared with naturally occurring TReg cells
selected from steady PB of healthy volunteers. Given the potential
for heterogeneity of response between the different samples from
healthy volunteers, we utilized the one HMCL to provide
consistency in the in vitro model, though similar results were
generated using other MM cell lines (JIM3, JJN3 & RPMI8226-
data not shown). When CD4+CD25- T-cells were selected as the
starting population, the level of FoxP3 expression was significantly
greater than naturally occurring TReg cells either from the PB of
healthy controls or patients with MM (15856101 vs
884667,p,0.0001, Kruskal-Wallis test; Figure 2A). Next, using
a sequential gating strategy, we examined the expression of key
surface markers on CD4+CD25+FoxP3+ T-cells. tTReg cells
demonstrated a similar level of CD127 (p = 0.413) and CD4
(p = 0.415) expression but demonstrated significantly higher levels
of CD25 (43,49266800 vs 18966137,p,0.0001), GITR (7065 vs
1063,p,0.001) and PD-1 (49.869 vs 5.360.8,p = 0.003), as
illustrated in Figure 2B and C. With regards to CD62L, there was
an overall lower mean fluorescence intensity (MFI) compared to
naturally occurring TReg cells (88.960.54 vs 97.360.54, p = 0.008;
Figure 2C), but a bi-phasic pattern of expression suggests two
populations of cells, some of which demonstrated similar
expression of CD62L as naturally occurring TReg cells
(Figure 2C). To determine the clonality of tumour-induced TReg
cells, CD4+CD25+CD127Dim T-cells were FACS sorted after 7
days of co-culture with mitomycin-C treated HMCL and DNA
prepared from sorted cell populations. TCRG PCR was performed
on genomic DNA derived from the tTReg cells. The spectrograph
indicates multiple ‘‘spikes’’ representative of a polyclonal popula-
tion in respect to the TCRG rearrangements, compared to a single
‘‘spike’’ representative of a monoclonal population (Figure S1).
tTReg Cells though Functionally Similar to nTReg Cells
Produce Interferonc
It has been reported that TReg cells from tumour-bearing hosts
demonstrate altered suppressive capabilities [9,23] though our
studies in myeloma patients demonstrate that TReg cells are
functionally active in suppression of autologous T-cell responses to
TCR stimulation [14]. First we sought to determine the
proliferative response of tTReg cells to TCR-mediated stimulation.
CD4+CD25- T-cells were isolated and co-cultured with HMCL for
7 days then CD4+CD25+CD127Dim T-cells (tTReg cells) were
FACS-sorted. tTReg cells were stimulated using CD3/CD28-
coated beads for 5 days, determining their proliferative response
by tritiated thymidine incorporation, comparing their response to
sorted nTReg cells from healthy donors and patients with
myeloma, similarly stimulated. tTReg cells demonstrated greater
proliferative responses to TCR-mediated stimulation compared
with nTReg cells from normal controls and MM patients, who
demonstrated the weakest proliferative responses
(1619361860 cpm vs 15106314 cpm vs 605673 cpm, p,0.001;
1 way ANOVA). Next we examined their suppressive capabilities.
tTReg cells generated in a 7 day co-culture were FACS-sorted and
co-cultured with autologous T-cells stimulated with CD3/CD28-
coated beads at the ratios described, for 5 days. The suppressive
capacity of tTReg cells was compared with nTReg cells from healthy
controls. We demonstrate that tTReg cells were able to suppress
anti-CD3/anti-CD28-induced T-cell proliferation in a dose
dependent fashion similar to naturally occurring TReg cells
(Figure 3A). Next we sought to determine the cytokine production
by tTReg cells in this culture system. When the supernatant was
analysed for IL-10 on Day 7, the co-culture of T-cells with HMCL
generated significantly higher levels of IL-10 compared to HMCLs
or CD4+ CD25- T-cells cultured alone (p,0.001; Figure 3B).
However, when the production of IL-10 by tTReg cells was
determined at the single-cell level by FACS, very few tTReg cells
produced IL-10 (Figure 3C). When the culture supernatant was
examined for the level of Interferonc (IFNc), the co-culture of T-
cells with HMCL generated significantly higher levels of IFNc
compared to either HMCLs or CD4+CD25- T-cells cultured alone
(p,0.0006; Figure 3D). We sought to determine the cellular origin
of IFNc and demonstrated that IFNc-producing tTReg cells could
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readily be identified, contributing to the production of IFNc
(Figure 3E). Analysis of nTReg cells from peripheral blood of
healthy age-matched controls and patients with MM demonstrates
a subset, albeit small subset, of nTReg cells that produce IFNc
(Figure 3F).
It is known that the effector T-cell lineage shows great plasticity
and that human TReg cells can differentiate into IL-17-producing
cells [24,25]. When tTReg cells were generated in our in vitro
culture model, a significant production of IL-17 was noted in the
supernatant after 7 days of co-culture of CD4+CD25- T-cells with
HMCL (30618 pg/ml vs 0.260.1 pg/ml; p,0.001; Figure 4A).
Therefore, we wished to determine if Th17 cells could be
generated directly from tTReg cells and thus, characterizing the
plasticity of tTReg cells generated in our in vitro model, compared to
naturally occurring TReg cells. CD4
+CD25- T-cells co-cultured
with mitomycin-C-treated HMCL for 7 days were FACS-sorted
and re-stimulated with CD3/CD28-coated beads with rhIL22
20 U/ml for 5 days. For comparison, naturally occurring TReg
cells were sorted using Miltenyi columns, co-cultured with
mitomycin-C-treated HMCL for 7 days, then FACS-sorted and
stimulated under identical conditions. After re-stimulation, a sub-
population of IL-17-producing CD4+ T-cells was identified from
the FACS-sorted tTReg cells, similar to nTReg cells (4.08%62.0 of
nTReg cells vs 3.62%62.0 of nTReg cells, p = 0.87; Figure 4B).
Closer analysis demonstrated that a smaller sub-population of
FoxP3 and IL-17 double positive cells were generated, in similar
quantities from both nTReg cells and tTReg cells (3.6%62.4 of
nTReg cells vs 2.7%61.8 of tTReg cells, p = 0.7; Figure 4C).
Myeloma-generated Regulatory T-cells are Induced by
Surface ICOS/ICOS-L Interactions not Tumour-derived
TGFb
The mechanisms for controlling the induction and expansion of
TReg cells remains to be fully clarified with some investigators
demonstrating soluble factors as central to induction whilst others
emphasize cell-to-cell contract, especially with dendritic cell
contact, as key [26,27,28]. We adapted our antigen presenting
cell-free in vitro model to investigate the role of humoral factors
versus contact mediation. CD25-CD4+ T-cells were isolated from
PB and co-cultured with mitomycin C-treated HMCL for 7 days
with and without transwell separation. The generation of
CD4+CD25+Foxp3+ TReg cells through co-culture with HMCL
was significantly reduced by abolishing cell-to-cell contact
(30.7%65 CD4+ tTReg cells vs 0.11%60.04 CD4
+ tTReg cells,
n = 7, p,0.001; Figure 5A). The inhibition of tumour-generated
CD4+ TReg cells through abolition of cell-to-cell contact was
Figure 2. Phenotypic characteristics of tumour-induced regulatory T-cells. A. FoxP3 expression, as determined by mean fluorescence
intensity (MFI) in natural TReg cells from healthy controls (Control PB, n = 43), PB from patients with MM (MM PB, n = 43) and tTReg cells (n = 15)
generated in co-culture from CD4+CD25- T-cells (Kruskal-Wallis test). Results represent all experiments, expressed as mean6 SEM and analyzed using
a 1-way ANOVA and student t-test. B. Representative histograms of naturally occurring TReg cell and tTReg cell surface expression of CD127, PD-1, GITR
and CD62L. C. Summary of surface expression profiling of natural TReg cells and tTReg cells generated in co-culture, gated on FoxP3
+CD25+CD4+ T-cells
(n = 4), expressed as mean fluorescence intensity (MFI). Results represent all experiments, expressed as mean 6 SEM and analyzed using student t-
test (*p,0.003, **p,0.0001).
doi:10.1371/journal.pone.0035981.g002
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Figure 3. Functional characteristics of tumour-induced regulatory T-cells. A. Suppression of anti-CD3/anti-CD28-induced autologous T-cell
proliferation by tumour-generated and naturally occurring TReg cells (n = 3), as determined by tritiated thymine incorporation. Results expressed as
counts per minute (cpm)6 SEM representing assays performed in triplicate. Key: Unstim – resting CD4+CD25- T cells, Stim – CD3/CD28 stimulated
CD4+CD25- T-cells, 4:1 etc – ratio of stimulated autologous T-cells to TReg cells. B. The generation of IL-10 in co-cultures of CD25
-CD4+ sorted T-cells
and HMCL, compared with HMCl alone and culture medium (n= 6, p = 0.0004). Results represent all experiments, expressed as mean6SEM and
analyzed using student t-test. C. IL-10 production by tTReg cells after 7 days of co-cultures of CD25
-CD4+ sorted T-cells and HMCL. Results represent all
experiments, expressed as mean6SEM (n= 3) and analyzed using student t-test. D. IL-10 production by tTReg cells after 7 days of co-cultures of
CD25-CD4+ sorted T-cells and HMCL. Results represent all experiments, expressed as mean6SEM (n= 3) and analyzed using student t-test. E.
Representative flow cytometry plots demonstrating the generation of IFNc+FoxP3+CD25+CD4+ T-cells from CD4+CD25- T-cells in a 7 day co-culture
assay with mitomycin C-treated U266B cells. F. The proportion of IFNc-producing FoxP3+CD25+CD4+ T-cells detectable in the peripheral blood of age-
matched controls (n = 15), patients with MM (n= 15) and tTReg cells generated in vitro after 7 days of co-cultures of CD25-CD4+ sorted T-cells and
HMCL (n = 3). Histograms represent IFNc production by cells gated on FoxP3/CD25/CD4 positive staing. Results expressed as mean6SEM.
doi:10.1371/journal.pone.0035981.g003
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associated with a reduction in the production of IL-10
(69.8633.6 pg/ml vs 6.360.01 pg/ml, n = 3, p = 0.079) and IFNc
(1215464174 pg/ml vs 0.0460.01 pg/ml, n = 3, p,0.001).
The role that surface TGFb plays in the induction and, in
conjunction with IL-10, the propagation of TReg cells has been
extensively studied in both human and murine systems [22]. We
therefore wished to determine the role that TGFb may play in the
generation of tTReg cells in our model. Whilst HMCL produce
soluble TGFb (data not shown) they express the modulatory
cytokine on their surface (Figure 5B) in addition to HLA class II
(DR) and the negative co-stimulatory molecule (second signal)
ICOSL (CD275). Therefore, CD4+ CD25- T-cells were isolated
from PB and co-cultured with mitomycin C-treated HMCL for 7
days with and without the specific TGFb antagonist, Latency
Associated Peptide (LAP) and an anti-TGFb monoclonal antibody
(MoAb). Neither LAP nor anti-TGFb MoAb demonstrated
significant inhibition of tTReg cell generation in our in vitro model
(Inhibition with anti-TGFb MoAb: 10.5%66.3 at 10 mM and
18.4%623 at 100 mM, n = 3; Inhibition with LAP: 9.6%64.6 at
10 mM and 5.0%60.1 at 100 mM, n = 3; Figure 5C Data).
Similarly, the use of anti-IL-10 MoAb failed to demonstrate any
significant inhibition of tTReg cell generation (7.5%62.5 at 10 mM
and 4.3%64.1 at 100 mM, n = 3, Figure 5C).
The B7 family members, ICOS/ICOSL have previously been
implicated in TReg cell generation. When examined, HMCL
express surface ICOS-L (Figure 5B). We therefore determined the
level of ICOS expression on newly generated tTReg cells and
nTReg cells. A mean of 65.6%67 tTReg cells expressed surface
ICOS (n = 5) compared with 6.6%61.5 nTReg cells from age-
matched controls (n = 14) and 8.1%61.3 nTReg cells from patients
with MM (n = 10; p,0.0001; Figure 5D). Thus we added an anti-
ICOS-L MoAb, in increasing concentrations, to CD4+CD25- T-
cells isolated from PB and co-cultured with mitomycin C-treated
HMCL for 7 days. The anti-ICOSL was able to demonstrate a
reduction in tTReg cell generation with an incremental inhibitory
effect with increasing concentrations (Inhibition of tTReg cell
Figure 4. Natural and tumour-induced regulatory T-cell plasticity. A. The generation of IL-17 in co-culture supernatants of CD25-CD4+ sorted
T-cells with HMCL, compared with HMCl alone and culture medium (n= 3). Results represent all experiments, expressed as mean6SEM. B.
Representative dot-plots of IL-17 producing cells generated from re-stimulation of sorted tumour-generated and naturally occurring TReg cells after 5
days of re-stimulation. C. The proportion of IL-17 producing cells generated from re-stimulation of sorted tumour-generated and naturally occurring
TReg cells, expressing FoxP3 after 5 days of re-stimulation, expressed as a percentage of CD4
+ T-cells. Results expressed as mean6SEM.
doi:10.1371/journal.pone.0035981.g004
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generation: 29.2%610 at m1M, 32.3%69.5 at 10 mM and
57.6%614.5 at 100 mM, n = 6, Figure 5E).
Discussion
The efficient generation of an immune response is coupled with a
regulatory system to limit that response, preventing the destruction
of healthy cells and tissues [29]. However, transformed malignant
tissue may adopt one or more mechanisms to interfere with either
the effector immune response or the regulatory cell compartment in
an attempt to evade immune surveillance [30,31,32,33,34]. In
myeloma, both dysfunctional effector responses and augmented
regulatory cell compartments have been described [9,12,35,36]. To
date, the origin of the expanded regulatory T-cell population has
remained elusive. We therefore sought to elucidate a causal
relationship between the tumour cell in myeloma and TReg cell
generation. Our model system demonstrates, for the first time, a
direct induction of TReg cells (tTReg cells) by both fresh myeloma
cells and cell lines that demonstrate the phenotype and function-
ality of TReg cells whilst inducing IL-10 production in non TReg
cells. However, phenotypic differences between tTReg cells induced
and naturally occurring TReg cells were noted. In particular tTReg
cells demonstrated a CD25HighFoxP3HighGITR+PD-1+ phenotype,
distinct from naturally occurring TReg cells. IFNc-producing
regulatory T cells have been described in the setting of intestinal
infection and allograft rejection and evidence suggests a central role
of IFNc in inducible TReg cell generation [37,38]. IFNc cellular
effects are mediated through STAT1 phoshorylation and it is
known than there is a STAT1 binding site in the proximal region of
the FoxP3 gene promoter in humans (but not mice) [39,40]. In
addition to which, IFNc has been shown to mediated FoxP3 gene
induction in synergy with IL-27[41]. Here we demonstrate for the
first time in a cancer setting, the generation of inducible TReg cells
from CD4+CD25- T cells where a subset produce IFNc in vitro. In
addition, similar to naturally occurring TReg cells,
CD4+CD25+CD127Low FACS sorted tTReg cells demonstrate
lineage plasticity by differentiating into IL-17-producing T-cells
following further TCR-mediated stimulation [24,42]. Further-
more, data published to date, has demonstrated a central role for
antigen presenting cells (APC) in the interactions of tumour cells
and TReg cells. However, in our in vitro system, myeloma tumour
cells generate and expand tTReg cells in an APC-free manner, that
is directly inducing CD4+CD25- T-cells. The importance of the
generation of previously considered pro-inflammatory cytokines in
the generation and or propagation of TReg cells in cancer remain to
be elucidated.
Figure 5. In vitro mechanisms of tumour regulatory T-cell induction. A. The generation of FoxP3+CD25+CD4+ tTReg cells from CD4
+CD25- T-
cells, expressed as a percentage of CD4+T-cells, in a co-culture assay with mitomycin C-treated U266 cells with and without transwell inserts (n = 7).
Results represent all experiments, represented as mean6SEM and analysed using a student t-Test. B. Surface expression of HLA-DR, ICOSL (CD275)
and TGFb by human myeloma cell lines. C. Inhibition of tTReg cells generation from CD4
+CD25- T-cells by co-culture with HMCL (n = 3) through
blockade of TGFb and IL-10 using monoclonal antibodies and Latency-associated Peptide (LAP). Results represent all experiments, expressed as mean
(6SEM). D. Surface expression of ICOS by TReg cells, presented as both percentage expression of CD4
+CD25+FoxP3+ cells and representative dot plots.
Results represent all experiments, expressed as mean 6SEM (n= 3) and analysed using a student t-test. E. Inhibition of tTReg cells generation from
CD4+CD25- T-cells by co-culture with HMCL through blockade of anti-ICOS-L (aICOS 1, 10, 100 mM) monoclonal antibody (n = 6), expressed as
percentage of CD4+ T-cells and percent inhibition of tTReg cell generation. Results represent all experiments, illustrated as median with maximum and
minimum values and analysed using a student t-test.
doi:10.1371/journal.pone.0035981.g005
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In patients with cancer, TReg cells are continuously exposed to
tumour antigen (TA), either directly or through the tumour micro-
environment which in turn, results in high levels of ICOS
expression as has been demonstrated in melanoma and prostate
cancer [7,43]. TReg cells generated in this environment produce
high levels of IL-10, which mediates their suppressive capabilities,
especially dendritic cell function [44]. We demonstrate with our
in vitro model that in myeloma, ICOS-L+ tumour cells directly
induce tTReg cell generation mediated in a contact-dependent
manner, in the absence of antigen-presenting cells, which is
inhibited significantly though not totally using anti-ICOSL
monoclonal antibodies. This model of induction tTReg cell
however, does not account for chronic antigen stimulation by
the tumour-bearing host, nor does it this culture system take
allowances of the effects of immunomoduatory drugs such as
steroids and IMiDs (Thalidomide, Lenalidomide, Pomalidomide)
which may account for differences in ICOS expression between
tTReg cell and TReg cells from MM patients, a significant level of
IL-10 is produced though this contributes minimally to the
generation of tTReg cells (as evidenced by lack of inhibition
through monoclonal antibody blockade). Furthermore, although
IL-10 production by ICOS-induced TReg cells has been docu-
mented in both human and murine in vitro systems [45,46,47], the
tTReg cells induced in our system did not produce IL-10.
The role of TGFb in both the generation of TReg cells and in
the mediation of their suppressive effects has been the subject of
conflicting reports and may relate to the experimental design of
in vitro systems used to study this relationship. In murine model
systems, TGFb-mediated FoxP3 induction in naı¨ve T-cells
augmented by IL-2, produce TReg cells with a suppressive
phenotype though are rendered hypo-responsive to TCR-mediat-
ed stimulation [4,48,49]. In contrast, other investigators have
demonstrated TGFb independence in both the generation and
mediation of suppression [50,51,52]. Murine prostatic and renal
cell cancer cells have been shown in vitro to generate TReg cells
mediated through TGFb. We have previously shown TGFb to
have a central role in myeloma-mediated effector cell dysfunction
and is detected at high level in peripheral blood and bone marrow
[12,36]. However, the data from our in vitro model did not
demonstrate a prominent role for TGFb in the induction of tTReg
cell generation, despite the production of TGFb in co-culture
supernatant (data not shown) and expressed on the surface of
tumour cells.
Recent studies have suggested a close relationship between
CD4+CD25+FoxP3+ TReg cells and pro-inflammatory IL-17-
producing T helper cells (Th17) [53]. In our studies, we
demonstrate that tTReg cells have a capacity, upon TCR-mediated
stimulation to generate IL-17 producing T-cells, both CD4+FoxP3+
and CD4+FoxP3- cells, indicative of a plasticity of the tTReg cells,
similar to previous reports [53,54,55]. More recently, it has ben
shown that different myeloid-derived cellular subsets
(CD14+HLA-DRDim vs CD14+HLA-DR+) can induce both TReg
cell and Th17 cells, with a recognized degree of plasticity [56].
However, our in vitro model system is APC-free and devoid of the
proposed myeloid-derived cellular subsets. Though the tTReg cells
were generated by co-culture with HMCL, in the absence of
additional TCR-mediated stimulation, the plasticity we observed
with these tTReg cells was purely upon TCR-mediated stimulation
in the absence of HMCL and suggests an independent functional
plasticity of tTReg cells.
In summary, our in vitro studies demonstrate that the tumour
cells of Myeloma are capable of inducing T-cells with the
phenotypic and functional characteristics of TReg cells, associated
with the production of IL-10 and IFNc The induction of TReg cells
is mediated by cell-to-cell contact with the ICOS/ICOS-L system
demonstrating a central role in the induction. The data presented
here offers a better understanding of the immune evasion adopted
by MM tumour cells offering a potential opportunity to
manipulate the tumour-bearing host immune micro-environment
pharmacologically. The pre-clinical data presented here offers a
scientific basis for the development of suitable clinical research
protocols to test this in vivo.
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Figure S1 DNA PCR analyses of TCRG rearrangements
of FACS sorted tTReg cells performed using the
BIOMED-2 multiplex strategy. Representative example of 3
experiments. Positive control used was peripheral blood from a
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